A Global Pattern, A Familiar Promise

Across regions, drug misuse continues to shape public health pressures in different ways. In North America, the opioid crisis has stretched emergency departments, addiction services and long-term care systems for over a decade.

In parts of Africa and Asia, synthetic drug markets are expanding, introducing new treatment demands into already resource-constrained health systems. In Europe and elsewhere, shifting patterns of stimulant and cannabis use are raising fresh clinical and policy questions.

At the same time, a familiar phrase echoes through health strategies and policy documents: prevention is cheaper than treatment. It sounds logical, responsible and efficient.

If that is true, then why do health systems still appear to intervene most heavily at the point of crisis? What is the price of waiting and how much does it cost our health systems? This is not a moral question, it is a structural one, and it sits at the centre of how modern health systems allocate attention, funding and urgency.

What Prevention Actually Means in Health Terms

Prevention, in the context of drug misuse, is often reduced to awareness campaigns or school talks. But within health systems, it is broader and more layered than that. It includes primary care screening for risky substance use; early mental health support for individuals whose trauma, anxiety or depression may increase vulnerability

Prevention also includes harm-reduction services designed to reduce overdose and infectious disease transmission; community-based outreach and public health education grounded in evidence rather than stigma and integrated care models that identify risk before dependency becomes entrenched.

Prevention is not a single programme, it is a series of earlier, lower-cost interventions designed to interrupt escalation. Treatment, by contrast, tends to enter the picture when substance use has already progressed.

At that stage, health systems are managing overdoses, acute psychiatric crises, organ damage, infectious complications or long-term substance use disorders that require specialist, sustained care. The financial difference between those stages is not subtle.

The Escalation Ladder as Costs Multiply

Drug misuse rarely begins at the most expensive point, it progresses. Occasional or experimental use may not immediately trigger clinical intervention, but when use becomes regular and problematic, health consequences often follow.

These may begin with mental health deterioration, sleep disruption, anxiety, depression or cognitive impairment. Primary care visits increase. Crisis presentations become more frequent.

As dependency develops, health systems begin to absorb more intensive costs. Emergency department admissions for overdose or acute intoxication require specialist staff, monitoring equipment and often inpatient beds.

Psychiatric services may be needed for severe mood disorders, psychosis or dual diagnoses. In some cases, intensive care is required for respiratory depression, organ failure or severe complications.

Longer-term consequences add another layer. Chronic liver disease, cardiovascular complications, neurological damage and increased vulnerability to infectious diseases create ongoing clinical management needs.

Patients may require long-term outpatient follow-up, medication-assisted treatment, specialist consultations and repeated admissions. Each stage requires more workforce time, more infrastructure and more sustained funding.

This is where the price of waiting becomes visible. When intervention occurs late, the cost per patient rises significantly. Bed occupancy increases. Specialist services become congested. Workforce burnout intensifies. Resources that could support broader population health are redirected to managing avoidable crises. Health systems do not only pay financially. They pay operationally.

The Prevention Paradox, the Seen vs. Unseen 

If early intervention is less costly and less disruptive, why does it remain structurally secondary? One explanation lies in visibility. Acute crises are immediate and undeniable, and care for crisis patients is ethically and clinically non-negotiable.

For example, an overdose in an emergency department demands response, a psychiatric breakdown requires urgent care and  patient in organ failure cannot be postponed. Prevention, by contrast, is quieter and when it works, nothing dramatic happens; n individual does not develop dependency, an overdose does not occur nor does a chronic condition does not materialise. 

Another factor is timing. Prevention savings often appear years later, while treatment costs are immediate and measurable. Political cycles and budget frameworks tend to favour short-term, visible outcomes. The long-term avoidance of cost is harder to quantify and easier to defer.

There is also structural fragmentation. Public health departments may oversee prevention initiatives, while acute care budgets sit elsewhere. Mental health services may be funded separately from primary care. When savings occur, they do not always return to the budget that made the initial investment. This weakens the incentive to prioritise early action.

None of this suggests that health leaders are unaware of prevention’s value. On the contrary, the rhetoric is consistent but the question is whether health systems are designed in ways that make early intervention structurally central rather than aspirational.

The Health System Strain

When drug misuse progresses unchecked, the impact radiates across the health system. Workforce pressures intensify, emergency departments experience higher demand and longer waiting times, mental health services face increased caseloads and more complex presentations.

Consequently, inpatient beds are occupied for longer periods, reducing capacity for other acute needs. 

Clinicians working in addiction medicine, psychiatry and emergency care often operate in high-stress environments with rising demand and limited expansion in staffing. The result is not only higher cost per patient, it is reduced system flexibility and staff burnout.

When resources are concentrated on late-stage management, there is less room for innovation, prevention expansion or broader health improvement efforts. 

It would be inaccurate to suggest that prevention is entirely neglected. Many countries have implemented harm-reduction programmes, expanded medication-assisted treatment and invested in community mental health services.

Public health campaigns have evolved beyond simplistic messaging toward more nuanced approaches. Yet the broader pattern where crisis response absorbs the majority of urgency and visibility remains.

This is not because prevention lacks evidence as research consistently shows that early intervention reduces long-term harm and cost. The difficulty lies in translating that evidence into sustained structural prioritisation.

When budgets tighten, prevention funding is often perceived as more flexible than acute services. When workforce shortages intensify, attention shifts toward stabilising crisis points. When headlines focus on overdose spikes or emergency surges, resources follow. Over time, this reactive cycle becomes normalised.

Reconsidering What Cost Means

When discussions about drug use focus primarily on individual responsibility, the systemic implications are obscured. Health systems, however, experience substance misuse as recurring demand, rising complexity and escalating expenditure.

Cost is not only the financial outlay, it is the opportunity cost of beds unavailable for other patients, the diversion of specialist time from preventive care to crisis stabilisation and the cumulative strain that limits system resilience during other public health emergencies. Seen this way, the price of waiting is not abstract.

It is embedded in daily operations. If prevention is framed merely as a social good, it can be deprioritised. If it is understood as core health infrastructure, a structural investment that protects capacity and reduces long-term strain, its position within planning may look different.

Beyond hospitals and clinics, substance misuse also affects social care systems, workplace productivity and, in many countries, criminal justice budgets. But even if we look strictly at healthcare alone, the financial and operational burden is already substantial. 

Returning to the Question

Prevention is widely acknowledged as cheaper than late-stage treatment and the logic for this is clear. Early screening costs less than intensive care. Community outreach costs less than chronic organ failure management.

Timely mental health support costs less than repeated emergency admissions. Yet the distribution of urgency within many health systems tells another story. The question is not whether prevention works. It is whether health systems are organised to make it central rather than secondary.

Until early intervention is funded and structured with the same consistency as crisis care, the cycle is likely to continue. Acute services will absorb demand, specialist teams will manage escalating complexity and costs will rise incrementally, then significantly.

The price of waiting does not arrive all at once. It accumulates quietly at first, then visibly within the very systems designed to protect population health. And if prevention truly is cheaper, the more pressing question may not be whether we can afford to invest earlier, but whether health systems can continue to afford not to.

Sources consulted

• Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study: https://www.healthdata.org/research-analysis/library/global-burden-amphetamine-cannabis-cocaine-and-opioid-use-204-countries
• UNODC World Drug Report 2024: https://www.unodc.org/documents/data-and-analysis/WDR_2024/WDR24_Contemporary_issues.pdf
• Improving public health: https://www.oecd.org/en/topics/improving-public-health.html